SNORD28: SNORD28 is a small nucleolar RNA (snoRNA) that has been implicated in various diseases, including non-small cell lung cancer (NSCLC) and breast cancer [PMC8677010]. In NSCLC, upregulation of SNORD28 is associated with shorter overall survival, along with the upregulation of SNORD78 and SNORD66 [PMC8677010]. In breast cancer patients, SNHG1, SNORD28, and sno-miR-28 are significantly upregulated in tumor tissues compared to normal tissues [PMC9404758]. sno-miR-28, derived from SNORD28, directly targets the p53-stabilizing gene TAF9B [PMC9149963]. Activation of p53 leads to downregulation of the expression levels of SNORD25, SNORD28, and sno-miR-28 in H1299 cells [PMC4465335]. Although a small RNA derived from SNORD28 is the most abundant small RNA recruited to AGO (Argonaute protein), SNORD29 is the most abundantly expressed snoRNA derived from SNHG1 [PMC4465335]. TaqMan gene expression assays were used to quantify small RNAs including miRNAs and snoRNAs such as miR-21, miR-155, miR-16, miR-24 as well as Custom TaqMan assays for specific snoRNAs including SNORD25 and SNORD28 [PMC4465335, PMC7154078]. In breast cancer patients with disease progression compared to those without progression, differential expression analysis revealed increased expression of two snoRNAs (SNORD28 and SNORD115-5) and one piRNA (piR-33202) [PMC9644097]. In influenza-A-virus-infected cells compared to non-infected cells, the relative expression level of SNORD22 increased while the levels of both SNOD26 and SNDOR29 decreased [PMC9696202].